A Phase 2 interventional study of REGN9933 and Enoxaparin in Venous Thromboembolism, sponsored by Regeneron Pharmaceuticals. Completed at 16 sites in 7 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2025-08-29.
Sponsored by Regeneron Pharmaceuticals · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Venous Thromboembolism with a site in Latvia — 2 open to participants now, 2 under way, 1 of them phase 3. Venous Thromboembolism · Latvia.
Among the 22 studies in Venous Thromboembolism with a site in Latvia, this one is the 16th largest by enrollment of the 19 interventional ones that give a count, is the only one that started in 2023, is one of 8 in phase 2, and was the 20th registered.
713 studies on the registry are indexed under Venous Thromboembolism; 147 are open to participants now.
Browse Venous Thromboembolism studies →2 of the 22 studies in Venous Thromboembolism with a site in Latvia are open now. Recruiting first, the newest first:
Regeneron Pharmaceuticals · Sites in Latvia, United States, Bulgaria and 5 more countries
Ages 18+
Manuel Monreal · Sites in Latvia, United States, Argentina and 26 more countries
A study can be open while its sites in Latvia have not opened yet or have stopped. Only those recruiting at a site in Latvia →
Of the 113 Venous Thromboembolism studies recruiting now, 90 (80%) set no upper age limit and 13 (12%) stop at 75 or younger; 9 take children under 18; 10 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 9 · Phase 3 11
First in 2001; this study’s year is marked. 1 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 373 is above the median of 241 across 402 interventional studies indexed under Venous Thromboembolism.
Median enrollment 1,146 across the 19 interventional studies, 19,076 across the 3 observational. Of the 20 that completed or were terminated, 10 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 22 have an industry lead sponsor. The 10 most frequent:
Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.
Regeneron Pharmaceuticals has 8 studies filed under Venous Thromboembolism — fewer than ten, so there is no comparison to draw.
2 of the studies in Venous Thromboembolism with a site in Latvia that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07015905Phase 3Regeneron PharmaceuticalsREGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in Adults | 2027-02-20 |
| NCT02832245Manuel MonrealComputerized Registry of Patients With Venous Thromboembolism (RIETE) | 2026-12 |
Add all 2 to your calendar (.ics) → With an account.
Among the 22 studies in Venous Thromboembolism with a site in Latvia, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of the study is to evaluate the efficacy of REGN9933 for the prevention of venous thromboembolism (VTE) after unilateral total knee arthroplasty (TKA), compared to enoxaparin
The secondary objectives of the study are:
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Other protocol-defined Inclusion/ Exclusion Criteria apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
REGN9933 will be administered by intravenous (IV) infusion
Drug: REGN9933
Enoxaparin will be administered by subcutaneous (SC) administration
Drug: Enoxaparin
Apixaban will be administered orally twice a day
Drug: Apixiban
Participants will receive a single dose of REGN9933 by IV infusion
Participants will receive enoxaparin by SC administration daily through the time of venography (or day 12, whichever is earlier)
Also known as: Lovenox
Participants will receive apixaban orally twice a day through the time of venography (or day 12, whichever is earlier)
Also known as: Eliquis
Percentage of Participants With Confirmed, Adjudicated Venous Thromboembolism (VTE) (REGN9933 vs Enoxaparin)
Composite endpoint that includes: asymptomatic deep DVT (deep venous thrombosis) detected by unilateral venography of the operated leg; confirmed symptomatic DVT of either leg; confirmed fatal or nonfatal pulmonary embolism (PE) including unexplained death for which PE cannot be ruled out
Time frame: Through Day 12
Number of Participants With Major Bleeding and Clinically Relevant Non-major (CRNM) Bleeding
International Society on Thrombosis and Hemostasis (ISTH) criteria for Major Bleeding and CRNM Bleeding as described in the protocol
Time frame: Through Day 12
Percentage of Participants With at Least One Treatment Emergent Adverse Event (TEAE)
A TEAE is any untoward medical occurrence in a participant administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment.
Time frame: Up to Day 75
Percentage of Participants With Major VTE (REGN9933 vs Enoxaparin)
Major VTE is a composite endpoint that includes: proximal DVT; confirmed symptomatic DVT of either leg; confirmed fatal or nonfatal PE including unexplained death for which PE cannot be ruled out
Time frame: Through Day 12
Percentage of Participants With DVT (REGN9933 vs Enoxaparin)
DVT measured by venography of the operated leg
Time frame: Through Day 12
Total REGN9933 Concentrations in Serum
The concentrations of REGN9933 over time were summarized by descriptive statistics by study arm for the overall population
Time frame: Days 0.0625 (post-dose), 4, 9, 29, and 74
Fold Change From Baseline in Activated Partial Thromboplastin Time (aPTT)
aPTT was used to measure the anticipated anticoagulant effect of REGN9933. Fold change is based on the follow-up value/baseline value within an arm.
Time frame: Days 1, 5, 10, 30, and 75
Fold Change From Baseline in Prothrombin Time (PT)
PT is a measure of extrinsic and/or common pathway function. Fold change is based on the follow-up value/baseline value within an arm.
Time frame: Days 1, 5, 10, 30, and 75
Number of Participants With Anti-REGN9933 Antibodies by Status
Immunogenicity characterized by anti-drug antibody (ADA) status
Time frame: Through Day 75
Number of Participants With Treatment-Emergent or Treatment-Boosted Anti-REGN13335 Antibodies by Maximum Titer Level
Immunogenicity characterized per drug molecule by ADA status
Time frame: Through Day 75
Percentage of Participants With Confirmed, Adjudicated VTE (Enoxaparin vs Apixaban)
Asymptomatic deep DVT detected by unilateral venography of the operated leg; confirmed symptomatic DVT of either leg; confirmed fatal or nonfatal pulmonary embolism (PE) including unexplained death for which PE cannot be ruled out.
Time frame: Through Day 12
| Milestone | REGN9933 | Enoxaparin | Apixaban |
|---|---|---|---|
| Started | 123 | 125 | 125 |
| Completed | 120 | 124 | 122 |
| Not completed | 3 | 1 | 3 |
| Withdrew: Withdrawal by subject | 3 | 1 | 3 |
Composite endpoint that includes: asymptomatic deep DVT (deep venous thrombosis) detected by unilateral venography of the operated leg; confirmed symptomatic DVT of either leg; confirmed fatal or nonfatal pulmonary embolism (PE) including unexplained death for which PE cannot be ruled out
| percentage of participants | REGN9933 | Enoxaparin |
|---|---|---|
| Percentage of Participants With Confirmed, Adjudicated Venous Thromboembolism (VTE) (REGN9933 vs Enoxaparin) | 17.2 | 22.2 |
International Society on Thrombosis and Hemostasis (ISTH) criteria for Major Bleeding and CRNM Bleeding as described in the protocol
| Participants | REGN9933 | Enoxaparin | Apixaban |
|---|---|---|---|
| Number of Participants With Major Bleeding and Clinically Relevant Non-major (CRNM) Bleeding | 0 | 0 | 0 |
A TEAE is any untoward medical occurrence in a participant administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment.
| percentage of participants | REGN9933 | Enoxaparin | Apixaban |
|---|---|---|---|
| Percentage of Participants With at Least One Treatment Emergent Adverse Event (TEAE) | 22.0 | 20.8 | 24.8 |
Major VTE is a composite endpoint that includes: proximal DVT; confirmed symptomatic DVT of either leg; confirmed fatal or nonfatal PE including unexplained death for which PE cannot be ruled out
| percentage of participants | REGN9933 | Enoxaparin |
|---|---|---|
| Percentage of Participants With Major VTE (REGN9933 vs Enoxaparin) | 0 | 2.6 |
DVT measured by venography of the operated leg
| percentage of participants | REGN9933 | Enoxaparin |
|---|---|---|
| Percentage of Participants With DVT (REGN9933 vs Enoxaparin) | 17.2 | 22.2 |
The concentrations of REGN9933 over time were summarized by descriptive statistics by study arm for the overall population
| milligrams/Liter (mg/L) | REGN9933 |
|---|---|
| Day 0.0625 (post-dose) | 65.6 ± 18.2 |
| Day 4 | 34.9 ± 9.65 |
| Day 9 | 23.7 ± 7.15 |
| Day 29 | 5.51 ± 3.47 |
| Day 74 | 0.140 ± 0.107 |
aPTT was used to measure the anticipated anticoagulant effect of REGN9933. Fold change is based on the follow-up value/baseline value within an arm.
| Fold Change | REGN9933 | Enoxaparin | Apixaban |
|---|---|---|---|
| Day 1 | 1.84 ± 0.245 | — | — |
| Day 5 | 2.26 ± 0.309 | 1.11 ± 0.143 | 1.16 ± 0.163 |
| Day 10 | 2.17 ± 0.443 | 1.04 ± 0.114 | 1.10 ± 0.117 |
| Day 30 | 1.56 ± 0.385 | 1.01 ± 0.149 | 1.04 ± 0.129 |
| Day 75 | 1.01 ± 0.132 | 1.01 ± 0.119 | 1.03 ± 0.120 |
PT is a measure of extrinsic and/or common pathway function. Fold change is based on the follow-up value/baseline value within an arm.
| Fold Change | REGN9933 | Enoxaparin | Apixaban |
|---|---|---|---|
| Day 1 | 1.01 ± 0.075 | — | — |
| Day 5 | 0.96 ± 0.086 | 0.94 ± 0.064 | 1.02 ± 0.091 |
| Day 10 | 0.95 ± 0.108 | 0.94 ± 0.073 | 1.00 ± 0.089 |
| Day 30 | 0.99 ± 0.220 | 0.97 ± 0.122 | 0.99 ± 0.183 |
| Day 75 | 0.94 ± 0.145 | 0.93 ± 0.092 | 0.94 ± 0.073 |
Immunogenicity characterized by anti-drug antibody (ADA) status
| Participants | REGN9933 |
|---|---|
| Negative | 118 |
| Pre-existing Immunoreactivity | 1 |
| Treatment-emergent (TE) Response | 0 |
| Treatment-boosted (TB) Response | 0 |
Immunogenicity characterized per drug molecule by ADA status
| Participants | REGN9933 |
|---|---|
| Low (<1,000) | 0 |
| Moderate (1,000 to 10,000) | 0 |
| High (>10,000) | 0 |
Asymptomatic deep DVT detected by unilateral venography of the operated leg; confirmed symptomatic DVT of either leg; confirmed fatal or nonfatal pulmonary embolism (PE) including unexplained death for which PE cannot be ruled out.
| percentage of participants | Enoxaparin | Apixaban |
|---|---|---|
| Percentage of Participants With Confirmed, Adjudicated VTE (Enoxaparin vs Apixaban) | 22.2 | 12.4 |
Collected over From date of signing informed consent form (ICF) up to end of study (approximately 105 days). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| REGN9933 | 0/123 (0%) | 4/123 (3.3%) | 9/123 (7.3%) |
| Enoxaparin | 0/125 (0%) | 1/125 (0.8%) | 11/125 (8.8%) |
| Apixaban | 0/125 (0%) | 2/125 (1.6%) | 16/125 (12.8%) |
| Event | REGN9933 | Enoxaparin | Apixaban |
|---|---|---|---|
| Atrial fibrillationCardiac disorders | 1/123 | 0/125 | 0/125 |
| CholecystitisHepatobiliary disorders | 1/123 | 0/125 | 0/125 |
| Device related infectionInfections and infestations | 1/123 | 0/125 | 0/125 |
| Urinary retentionRenal and urinary disorders | 1/123 | 0/125 | 0/125 |
| Angina pectorisCardiac disorders | 0/123 | 0/125 | 1/125 |
| Soft tissue infectionInfections and infestations | 0/123 | 1/125 | 0/125 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/123 | 0/125 | 1/125 |
| Event | REGN9933 | Enoxaparin | Apixaban |
|---|---|---|---|
| Anaemia postoperativeInjury, poisoning and procedural complications | 9/123 | 11/125 | 16/125 |
| Age, Continuous(Years) | REGN9933 | Enoxaparin | Apixaban | Total |
|---|---|---|---|---|
| Mean | 66.5 ± 7.73 | 66.6 ± 7.61 | 66.5 ± 7.69 | 66.5 ± 7.66 |
| Sex: Female, Male(Participants) | REGN9933 | Enoxaparin | Apixaban | Total |
|---|---|---|---|---|
| Female | 95 | 104 | 89 | 288 |
| Male | 28 | 21 | 36 | 85 |
| Ethnicity (NIH/OMB)(Participants) | REGN9933 | Enoxaparin | Apixaban | Total |
|---|---|---|---|---|
| Hispanic or Latino | 3 | 2 | 4 | 9 |
| Not Hispanic or Latino | 120 | 121 | 121 | 362 |
| Unknown or Not Reported | 0 | 2 | 0 | 2 |
| Race (NIH/OMB)(Participants) | REGN9933 | Enoxaparin | Apixaban | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 123 | 125 | 125 | 373 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: When Regeneron has received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication, has made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry), has the legal authority to share the data, and has ensured the ability to protect participant privacy.
Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
Data sharing details ↗ · vivli.org
Ran from May 2023 to primary completion in May 2024, 12 months.
Results were first posted in Jul 2025, 1 year 1 month after primary completion.
Of 27 phase 2 interventional studies under Venous Thromboembolism, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 50. This study's 12 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Amrecibart